Biopharma SHAKTI Initiative Launched with ₹10,000 Crore Outlay to Facilitate Domestic Biologics Production
The Union Budget 2026 has proposed a comprehensive biopharma strategy titled 'Biopharma SHAKTI' with an outlay of ₹10,000 crore over the next five years. The initiative aims to transform India into a global biopharmaceutical manufacturing hub by facilitating the domestic production of biologics and biosimilars. Key components include setting up three new National Institutes of Pharmaceutical Education and Research (NIPER) and strengthening the Central Drugs Standard Control Organisation (CDSCO) to meet global standards. This move addresses the rising burden of non-communicable diseases and seeks to provide affordable, high-quality complex medicines.
Key Points
- Biopharma SHAKTI has a five-year outlay of ₹10,000 crore for domestic biologics production.
- The focus is on complex medicines like biologics and biosimilars manufactured from living systems.
- Three new NIPERs will be established to boost research, education, and clinical trials.
- The CDSCO will be upgraded to align with international regulatory standards and speed up approvals.
Exam Facts
- Outlay: ₹10,000 crore.
- Duration: 5 years.
- Regulatory body: CDSCO (Central Drugs Standard Control Organisation).
- Educational institutes: NIPER (National Institute of Pharmaceutical Education and Research).
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.